Antisense technology for cancer therapy: does it make sense?

This publication has 51 references indexed in Scilit:

• Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene
  Gene, 1992
• Participation in Normal Immune Responses of a Metastasis-Inducing Splice Variant of CD44
  Science, 1992
• Directed Evolution of an RNA Enzyme
  Science, 1992
• Effect of the terminal phosphate derivatization of β- and α-oligodeoxynucleotides on their antisense activity in protein biosynthesis, stability and uptake by eucaryotic cells
  Biochimie, 1992
• Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides.
  The Journal of Experimental Medicine, 1992
• The cell membrane as a target for cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1991
• Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
  Science, 1991
• Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications
  JNCI Journal of the National Cancer Institute, 1989
• Effect of Antisense c- raf -1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma
  Science, 1989
• Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones.
  The Journal of Experimental Medicine, 1988